扩大细胞周期蛋白依赖性激酶4/6抑制剂在辅助和新辅助治疗中的适应证。
Extending indication of cyclin-dependent kinase 4/6 inhibitors in the adjuvant and neoadjuvant setting.
作者信息
Criscitiello Carmen, Viale Giulia, Curigliano Giuseppe
机构信息
Division of Experimental Therapeutics, European Institute of Oncology, Milan, Italy.
出版信息
Curr Opin Oncol. 2017 Nov;29(6):428-433. doi: 10.1097/CCO.0000000000000401.
PURPOSE OF REVIEW
A burst of recent activity has surrounded the study of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors for the treatment of metastatic breast cancer. The success of these drugs in the metastatic setting has pushed the evaluation of these agents in early-stage disease. The use of CDK 4/6 inhibitors as neoadjuvant and adjuvant therapy is a hot topic and several studies are underway.
RECENT FINDINGS
Ongoing studies are exploring the addition of CDK 4/6 inhibitors to endocrine therapy in early breast cancer.
SUMMARY
Identification of the optimal treatment combinations is the goal of current research. Finding biomarkers for patients' selection will be the goal of future research.
综述目的
近期围绕细胞周期蛋白依赖性激酶4/6（CDK 4/6）抑制剂治疗转移性乳腺癌的研究活动激增。这些药物在转移性疾病中的成功促使人们对其在早期疾病中的评估。将CDK 4/6抑制剂用作新辅助和辅助治疗是一个热门话题，多项研究正在进行中。
最新发现
正在进行的研究正在探索在早期乳腺癌的内分泌治疗中添加CDK 4/6抑制剂。
总结
确定最佳治疗组合是当前研究的目标。寻找用于患者选择的生物标志物将是未来研究的目标。
Zotero 插件